Biogen BIIB FUMADERM And ADUHELM — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's fumaderm and aduhelm — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's FUMADERM and ADUHELM — total revenue?
- Biogen (BIIB) reported FUMADERM and ADUHELM — total revenue of $0 in Q1 2026.
- How has Biogen's FUMADERM and ADUHELM — total revenue changed year-over-year?
- Biogen's FUMADERM and ADUHELM — total revenue decreased by 100.0% year-over-year, from $1.7M to $0.
- What is the long-term trend for Biogen's FUMADERM and ADUHELM — total revenue?
- Over 3 years (2022 to 2025), Biogen's FUMADERM and ADUHELM — total revenue has grown at a -45.5% compound annual growth rate (CAGR), from $13M to $2.1M.
- What does FUMADERM and ADUHELM — total revenue mean?
- This metric represents the total net sales generated from the specific product portfolio consisting of Fumaderm and Aduhelm. It reflects the commercial performance and market adoption of these legacy or specialized therapeutic assets within the company's broader neurology and immunology franchise. Tracking this revenue stream helps investors assess the lifecycle management and residual market contribution of these specific pharmaceutical products.